99 related articles for article (PubMed ID: 24658652)
1. Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy.
Wu A; Jia Y; Dong B; Tang L; Liu Y; Du H; Yuan P; Dong P; Ji J
Cancer Chemother Pharmacol; 2014 May; 73(5):885-93. PubMed ID: 24658652
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer.
Jia Y; Dong B; Tang L; Liu Y; Du H; Yuan P; Wu A; Ji J
Tumour Biol; 2012 Aug; 33(4):1151-8. PubMed ID: 22383294
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer.
Imano M; Itoh T; Satou T; Sogo Y; Hirai H; Kato H; Yasuda A; Peng YF; Shinkai M; Yasuda T; Imamoto H; Okuno K; Shiozaki H; Ohyanagi H
Eur J Surg Oncol; 2010 Oct; 36(10):963-8. PubMed ID: 20638818
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of neoadjuvant chemotherapy with modified FOLFOX7 regimen on the treatment of advanced gastric cancer.
Zhang J; Chen RX; Zhang J; Cai J; Meng H; Wu GC; Zhang ZT; Wang Y; Wang KL
Chin Med J (Engl); 2012 Jun; 125(12):2144-50. PubMed ID: 22884144
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
Persiani R; D'Ugo D; Rausei S; Sermoneta D; Barone C; Pozzo C; Ricci R; La Torre G; Picciocchi A
J Surg Oncol; 2005 Mar; 89(4):227-36; discussion 237-8. PubMed ID: 15726615
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.
Lee J; Im YH; Lee SH; Cho EY; Choi YL; Ko YH; Kim JH; Nam SJ; Kim HJ; Ahn JS; Park YS; Lim HY; Han BK; Yang JH
Cancer Chemother Pharmacol; 2008 Apr; 61(4):569-77. PubMed ID: 17508214
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Barone C; Cassano A; Pozzo C; D'Ugo D; Schinzari G; Persiani R; Basso M; Brunetti IM; Longo R; Picciocchi A
Oncology; 2004; 67(1):48-53. PubMed ID: 15459495
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma.
Chang J; Ormerod M; Powles TJ; Allred DC; Ashley SE; Dowsett M
Cancer; 2000 Dec; 89(11):2145-52. PubMed ID: 11147583
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer.
Inoue K; Nakane Y; Kogire M; Fujitani K; Kimura Y; Imamura H; Tamura S; Okano S; Kwon AH; Kurokawa Y; Shimokawa T; Takiuchi H; Tsujinaka T; Furukawa H
Eur J Surg Oncol; 2012 Feb; 38(2):143-9. PubMed ID: 22154885
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
14. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study.
Persiani R; Rausei S; Pozzo C; Biondi A; Barone C; Cananzi FC; Schinzari G; D'Ugo D
Ann Surg Oncol; 2008 Aug; 15(8):2146-52. PubMed ID: 18543037
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer.
Satomi D; Takiguchi N; Koda K; Oda K; Suzuki H; Yasutomi J; Ishikura H; Miyazaki M
Int J Oncol; 2002 Jun; 20(6):1167-71. PubMed ID: 12011994
[TBL] [Abstract][Full Text] [Related]
16. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome.
Tsamandas AC; Kardamakis D; Tsiamalos P; Liava A; Tzelepi V; Vassiliou V; Petsas T; Vagenas K; Zolota V; Scopa CD
Anticancer Res; 2009 Feb; 29(2):703-9. PubMed ID: 19331225
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pre-operative chemotherapy with docetaxel, cisplatin, and S-1 (DCS therapy) and curative resection for gastric cancer with pathologically positive para-aortic lymph nodes.
Oyama K; Fushida S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Nakagawara H; Tajima H; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Tani T; Fujimura T; Ohta T
J Surg Oncol; 2012 May; 105(6):535-41. PubMed ID: 22006649
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
Ajani JA; Winter K; Okawara GS; Donohue JH; Pisters PW; Crane CH; Greskovich JF; Anne PR; Bradley JD; Willett C; Rich TA
J Clin Oncol; 2006 Aug; 24(24):3953-8. PubMed ID: 16921048
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer.
Rocca A; Peruzzotti G; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Pietri E; Curigliano G; Giovanardi F; Maisonneuve P; Goldhirsch A; Colleoni M
Anticancer Drugs; 2006 Nov; 17(10):1201-9. PubMed ID: 17075320
[TBL] [Abstract][Full Text] [Related]
20. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases.
Becker K; Langer R; Reim D; Novotny A; Meyer zum Buschenfelde C; Engel J; Friess H; Hofler H
Ann Surg; 2011 May; 253(5):934-9. PubMed ID: 21490451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
